Abbott Rides High After Torcetrapib Collapse: Is Everything Old New Again?
This article was originally published in RPM Report
Executive Summary
The end of torcetrapib was bad news for Pfizer, and could be a death knell for the entire CETP inhibitor class. But it also makes Abbott's acquisition of Kos look prescient. Wall Street is taking notice.
You may also be interested in...
Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks
Between big-name statins going generic and high-profile blow-ups like torcetrapib, Cordaptive and Vytorin, cholesterol drug development has been tough going. Some drug companies think the next big thing in lipid management is something different altogether: prescription-grade supplements. It may be just the thing for a risk-averse FDA.
Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks
Between big-name statins going generic and high-profile blow-ups like torcetrapib, Cordaptive and Vytorin, cholesterol drug development has been tough going. Some drug companies think the next big thing in lipid management is something different altogether: prescription-grade supplements. It may be just the thing for a risk-averse FDA.
Torcetrapib's Silver Lining
What looks like bad news for the future of the CEPT inhibitor class of HDL-raising drugs may have a hidden silver lining for pharmaceutical companies interested in advancing the use of imaging as a clinical trial endpoint.